Northwest Bio narrows Q2 net loss to $9.2 million from year-ago period

• Northwest Biotherapeutics posted a Q2 net loss of USD 9.2 million, narrowing from a USD 15.4 million loss a year earlier.
• R&D expense fell 22.97% to USD 5.7 million, due to lower MHRA MAA-review costs and reduced stock-based compensation to consultants.
• G&A expense declined 10.67% to USD 6.7 million, on lower legal costs.
• For H1, net loss narrowed to USD 12.3 million from USD 34.7 million, helped by a USD 9.4 million non-cash derivatives gain.
• Operationally, the group stayed engaged in the UK MAA review, advanced UK manufacturing and leukapheresis capacity plans, and presented new Phase 3 IPD analyses at BNOS.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Northwest Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-097188), on August 14, 2026, and is solely responsible for the information contained therein.